BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

Role of post-translational modifications on the alpha-synuclein aggregation-related pathogenesis of Parkinson's disease

  • Yoo, Hajung (Department of Biomedical Science, Graduate School of Biomedical Science and Engineering, Hanyang University) ;
  • Lee, Jeongmin (Department of Biomedical Science, Graduate School of Biomedical Science and Engineering, Hanyang University) ;
  • Kim, Bokwang (Department of Biomedical Science, Graduate School of Biomedical Science and Engineering, Hanyang University) ;
  • Moon, Heechang (Department of Biomedical Science, Graduate School of Biomedical Science and Engineering, Hanyang University) ;
  • Jeong, Huisu (Department of Biomedical Science, Graduate School of Biomedical Science and Engineering, Hanyang University) ;
  • Lee, Kyungmi (Department of Medicine, College of Medicine, Hanyang University) ;
  • Song, Woo Jeung (Department of Medical Genetics, College of Medicine, Hanyang University) ;
  • Hur, Junho K. (Department of Biomedical Science, Graduate School of Biomedical Science and Engineering, Hanyang University) ;
  • Oh, Yohan (Department of Biomedical Science, Graduate School of Biomedical Science and Engineering, Hanyang University)
  • Received : 2022.03.28
  • Accepted : 2022.05.17
  • Published : 2022.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

Together with neuronal loss, the existence of insoluble inclusions of alpha-synuclein (α-syn) in the brain is widely accepted as a hallmark of synucleinopathies including Parkinson's disease (PD), multiple system atrophy, and dementia with Lewy body. Because the α-syn aggregates are deeply involved in the pathogenesis, there have been many attempts to demonstrate the mechanism of the aggregation and its potential causative factors including post-translational modifications (PTMs). Although no concrete conclusions have been made based on the previous study results, growing evidence suggests that modifications such as phosphorylation and ubiquitination can alter α-syn characteristics to have certain effects on the aggregation process in PD; either facilitating or inhibiting fibrillization. In the present work, we reviewed studies showing the significant impacts of PTMs on α-syn aggregation. Furthermore, the PTMs modulating α-syn aggregation-induced cell death have been discussed.

Keywords

Acknowledgement

This work was supported by Korea Drug Development Fund funded by Ministry of Science and ICT (MSIT), Ministry of Trade, Industry, and Energy, and Ministry of Health and Welfare (MOHW) (HN21C1258, Republic of Korea), by the National Research Foundation of Korea grants funded by MSIT (NRF-2019M3A9H1103783, NRF-2020R1A2C1009172; Republic of Korea), and by Korean Fund for Regenerative Medicine funded by MSIT and MOHW (2021M3E5E5096744, Republic of Korea). Kyungmi Lee was a trainee of the Medical Scientist Training Program at Hanyang University, College of Medicine. I sincerely apologize to colleagues whose work has not been cited in this review due to space limitations.

References

  1. Klein C and Westenberger A (2012) Genetics of Parkinson's disease. Cold Spring Harb Perspect Med 2, a008888 https://doi.org/10.1101/cshperspect.a008888
  2. Polymeropoulos MH, Lavedan C, Leroy E et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047 https://doi.org/10.1126/science.276.5321.2045
  3. Emamzadeh FN (2016) Alpha-synuclein structure, functions, and interactions. J Res Med Sci 21, 29 https://doi.org/10.4103/1735-1995.181989
  4. Spillantini MG, Crowther RA, Jakes R, Hasegawa M and Goedert M (1998) alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A 95, 6469-6473 https://doi.org/10.1073/pnas.95.11.6469
  5. Trojanowski JQ, Revesz T and Neuropathology Working Group on MSA (2007) Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol Appl Neurobiol 33, 615-620 https://doi.org/10.1111/j.1365-2990.2007.00907.x
  6. McCann H, Stevens CH, Cartwright H and Halliday GM (2014) alpha-Synucleinopathy phenotypes. Parkinsonism Relat Disord 20 Suppl 1, S62-S67 https://doi.org/10.1016/S1353-8020(13)70017-8
  7. Nishie M, Mori F, Yoshimoto M, Takahashi H and Wakabayashi K (2004) A quantitative investigation of neuronal cytoplasmic and intranuclear inclusions in the pontine and inferior olivary nuclei in multiple system atrophy. Neuropathol Appl Neurobiol 30, 546-554 https://doi.org/10.1111/j.1365-2990.2004.00564.x
  8. Fauvet B, Mbefo MK, Fares MB et al (2012) alpha-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem 287, 15345-15364 https://doi.org/10.1074/jbc.M111.318949
  9. Bartels T, Choi JG and Selkoe DJ (2011) alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477, 107-110 https://doi.org/10.1038/nature10324
  10. Lashuel HA, Petre BM, Wall J et al (2002) Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 322, 1089-1102 https://doi.org/10.1016/S0022-2836(02)00735-0
  11. Cremades N, Cohen SI, Deas E et al (2012) Direct observation of the interconversion of normal and toxic forms of alpha-synuclein. Cell 149, 1048-1059 https://doi.org/10.1016/j.cell.2012.03.037
  12. Chen SW, Drakulic S, Deas E et al (2015) Structural characterization of toxic oligomers that are kinetically trapped during alpha-synuclein fibril formation. Proc Natl Acad Sci U S A 112, E1994-E2003
  13. Mahul-Mellier AL, Burtscher J, Maharjan N et al (2020) The process of Lewy body formation, rather than simply alpha-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proc Natl Acad Sci U S A 117, 4971-4982 https://doi.org/10.1073/pnas.1913904117
  14. Danzer KM, Haasen D, Karow AR et al (2007) Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci 27, 9220-9232 https://doi.org/10.1523/JNEUROSCI.2617-07.2007
  15. Fusco G, Chen SW, Williamson PTF et al (2017) Structural basis of membrane disruption and cellular toxicity by alpha-synuclein oligomers. Science 358, 1440-1443 https://doi.org/10.1126/science.aan6160
  16. Peelaerts W, Bousset L, Van der Perren A et al (2015) alpha-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 522, 340-344 https://doi.org/10.1038/nature14547
  17. Li JY, Englund E, Holton JL et al (2008) Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 14, 501-503 https://doi.org/10.1038/nm1746
  18. Braak H, Ghebremedhin E, Rub U, Bratzke H and Del Tredici K (2004) Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 318, 121-134 https://doi.org/10.1007/s00441-004-0956-9
  19. Volpicelli-Daley LA, Luk KC, Patel TP et al (2011) Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72, 57-71 https://doi.org/10.1016/j.neuron.2011.08.033
  20. Yasuda T, Nakata Y and Mochizuki H (2013) alpha-Synuclein and neuronal cell death. Mol Neurobiol 47, 466-483 https://doi.org/10.1007/s12035-012-8327-0
  21. Benskey MJ, Perez RG and Manfredsson FP (2016) The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease. J Neurochem 137, 331-359 https://doi.org/10.1111/jnc.13570
  22. Sherer TB, Betarbet R, Stout AK et al (2002) An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci 22, 7006-7015 https://doi.org/10.1523/JNEUROSCI.22-16-07006.2002
  23. Scudamore O and Ciossek T (2018) Increased oxidative stress exacerbates alpha-synuclein aggregation in vivo. J Neuropathol Exp Neurol 77, 443-453 https://doi.org/10.1093/jnen/nly024
  24. Musgrove RE, Helwig M, Bae EJ et al (2019) Oxidative stress in vagal neurons promotes parkinsonian pathology and intercellular alpha-synuclein transfer. J Clin Invest 129, 3738-3753 https://doi.org/10.1172/jci127330
  25. Xilouri M, Brekk OR and Stefanis L (2013) alpha-Synuclein and protein degradation systems: a reciprocal relationship. Mol Neurobiol 47, 537-551 https://doi.org/10.1007/s12035-012-8341-2
  26. Seo J and Lee KJ (2004) Post-translational modifications and their biological functions: proteomic analysis and systematic approaches. J Biochem Mol Biol 37, 35-44
  27. Maltsev AS, Ying J and Bax A (2012) Impact of N-terminal acetylation of alpha-synuclein on its random coil and lipid binding properties. Biochemistry 51, 5004-5013 https://doi.org/10.1021/bi300642h
  28. Kang L, Moriarty GM, Woods LA, Ashcroft AE, Radford SE and Baum J (2012) N-terminal acetylation of alpha-synuclein induces increased transient helical propensity and decreased aggregation rates in the intrinsically disordered monomer. Protein Sci 21, 911-917 https://doi.org/10.1002/pro.2088
  29. Bartels T, Kim NC, Luth ES and Selkoe DJ (2014) Nalpha-acetylation of alpha-synuclein increases its helical folding propensity, GM1 binding specificity and resistance to aggregation. PLoS One 9, e103727 https://doi.org/10.1371/journal.pone.0103727
  30. Watson MD and Lee JC (2019) N-terminal acetylation affects alpha-synuclein fibril polymorphism. Biochemistry 58, 3630-3633 https://doi.org/10.1021/acs.biochem.9b00629
  31. Dikiy I and Eliezer D (2014) N-terminal acetylation stabilizes N-terminal helicity in lipid- and micelle-bound alpha-synuclein and increases its affinity for physiological membranes. J Biol Chem 289, 3652-3665 https://doi.org/10.1074/jbc.M113.512459
  32. Lorentzon E, Kumar R, Horvath I and Wittung-Stafshede P (2020) Differential effects of Cu(2+) and Fe(3+) ions on in vitro amyloid formation of biologically-relevant alpha-synuclein variants. Biometals 33, 97-106 https://doi.org/10.1007/s10534-020-00234-4
  33. Lima VA, do Nascimento LA, Eliezer D and Follmer C (2019) Role of Parkinson's disease-linked mutations and N-terminal acetylation on the oligomerization of alpha-synuclein Induced by 3,4-dihydroxyphenylacetaldehyde. ACS Chem Neurosci 10, 690-703 https://doi.org/10.1021/acschemneuro.8b00498
  34. Wang S, Yang F, Petyuk VA et al (2017) Quantitative proteomics identifies altered O-GlcNAcylation of structural, synaptic and memory-associated proteins in Alzheimer's disease. J Pathol 243, 78-88 https://doi.org/10.1002/path.4929
  35. Li Y, Zhao C, Luo F et al (2018) Amyloid fibril structure of alpha-synuclein determined by cryo-electron microscopy. Cell Res 28, 897-903 https://doi.org/10.1038/s41422-018-0075-x
  36. Tuttle MD, Comellas G, Nieuwkoop AJ et al (2016) Solid-state NMR structure of a pathogenic fibril of full-length human alpha-synuclein. Nat Struct Mol Biol 23, 409-415 https://doi.org/10.1038/nsmb.3194
  37. Alfaro JF, Gong CX, Monroe ME et al (2012) Tandem mass spectrometry identifies many mouse brain O-GlcNA-cylated proteins including EGF domain-specific O-GlcNAc transferase targets. Proc Natl Acad Sci U S A 109, 7280-7285 https://doi.org/10.1073/pnas.1200425109
  38. Morris M, Knudsen GM, Maeda S et al (2015) Tau posttranslational modifications in wild-type and human amyloid precursor protein transgenic mice. Nat Neurosci 18, 1183-1189 https://doi.org/10.1038/nn.4067
  39. Zhang J, Lei H, Chen Y et al (2017) Enzymatic O-GlcNA-cylation of alpha-synuclein reduces aggregation and increases SDS-resistant soluble oligomers. Neurosci Lett 655, 90-94 https://doi.org/10.1016/j.neulet.2017.06.034
  40. Levine PM, Galesic A, Balana AT et al (2019) alpha-Synuclein O-GlcNAcylation alters aggregation and toxicity, revealing certain residues as potential inhibitors of Parkinson's disease. Proc Natl Acad Sci U S A 116, 1511-1519 https://doi.org/10.1073/pnas.1808845116
  41. Marotta NP, Lin YH, Lewis YE et al (2015) O-GlcNAc modification blocks the aggregation and toxicity of the protein alpha-synuclein associated with Parkinson's disease. Nat Chem 7, 913-920 https://doi.org/10.1038/nchem.2361
  42. Marotta NP, Cherwien CA, Abeywardana T and Pratt MR (2012) O-GlcNAc modification prevents peptide-dependent acceleration of alpha-synuclein aggregation. ChemBioChem 13, 2665-2670 https://doi.org/10.1002/cbic.201200478
  43. Ryan P, Xu M, Davey AK et al (2019) O-GlcNAc modification protects against protein misfolding and aggregation in neurodegenerative disease. ACS Chem Neurosci 10, 2209-2221 https://doi.org/10.1021/acschemneuro.9b00143
  44. Lewis YE, Galesic A, Levine PM et al (2017) O-GlcNAcylation of alpha-synuclein at serine 87 reduces aggregation without affecting membrane binding. ACS Chem Biol 12, 1020-1027 https://doi.org/10.1021/acschembio.7b00113
  45. Vicente Miranda H, Szego EM, Oliveira LMA et al (2017) Glycation potentiates alpha-synuclein-associated neurodegeneration in synucleinopathies. Brain 140, 1399-1419 https://doi.org/10.1093/brain/awx056
  46. Chen L, Wei Y, Wang X and He R (2010) Ribosylation rapidly induces alpha-synuclein to form highly cytotoxic molten globules of advanced glycation end products. PLoS One 5, e9052 https://doi.org/10.1371/journal.pone.0009052
  47. Sharma N, Rao SP and Kalivendi SV (2019) The deglycase activity of DJ-1 mitigates alpha-synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ-1 in Parkinson's disease. Free Radic Biol Med 135, 28-37 https://doi.org/10.1016/j.freeradbiomed.2019.02.014
  48. Marino L, Ramis R, Casasnovas R et al (2020) Unravelling the effect of N(epsilon)-(carboxyethyl)lysine on the conformation, dynamics and aggregation propensity of alpha-synuclein. Chem Sci 11, 3332-3344 https://doi.org/10.1039/d0sc00906g
  49. Lee D, Park CW, Paik SR and Choi KY (2009) The modification of alpha-synuclein by dicarbonyl compounds inhibits its fibril-forming process. Biochim Biophys Acta 1794, 421-430 https://doi.org/10.1016/j.bbapap.2008.11.016
  50. Sevcsik E, Trexler AJ, Dunn JM and Rhoades E (2011) Allostery in a disordered protein: oxidative modifications to alpha-synuclein act distally to regulate membrane binding. J Am Chem Soc 133, 7152-7158 https://doi.org/10.1021/ja2009554
  51. Burai R, Ait-Bouziad N, Chiki A and Lashuel HA (2015) Elucidating the role of site-specific nitration of alpha-synuclein in the pathogenesis of Parkinson's disease via protein semisynthesis and mutagenesis. J Am Chem Soc 137, 5041-5052 https://doi.org/10.1021/ja5131726
  52. Giasson BI, Duda JE, Murray IV et al (2000) Oxidative damage linked to neurodegeneration by selective alphasynuclein nitration in synucleinopathy lesions. Science 290, 985-989 https://doi.org/10.1126/science.290.5493.985
  53. Hodara R, Norris EH, Giasson BI et al (2004) Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. J Biol Chem 279, 47746-47753 https://doi.org/10.1074/jbc.M408906200
  54. Norris EH, Giasson BI, Ischiropoulos H and Lee VM (2003) Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications. J Biol Chem 278, 27230-27240 https://doi.org/10.1074/jbc.M212436200
  55. Qiao HH, Zhu LN, Wang Y et al (2019) Implications of alpha-synuclein nitration at tyrosine 39 in methamphetamine-induced neurotoxicity in vitro and in vivo. Neural Regen Res 14, 319-327 https://doi.org/10.4103/1673-5374.244795
  56. Yamin G, Uversky VN and Fink AL (2003) Nitration inhibits fibrillation of human alpha-synuclein in vitro by formation of soluble oligomers. FEBS Lett 542, 147-152 https://doi.org/10.1016/S0014-5793(03)00367-3
  57. Fujiwara H, Hasegawa M, Dohmae N et al (2002) alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4, 160-164 https://doi.org/10.1038/ncb748
  58. Nakajo S, Tsukada K, Omata K, Nakamura Y and Nakaya K (1993) A new brain-specific 14-kDa protein is a phosphoprotein. Its complete amino acid sequence and evidence for phosphorylation. Eur J Biochem 217, 1057-1063 https://doi.org/10.1111/j.1432-1033.1993.tb18337.x
  59. Pronin AN, Morris AJ, Surguchov A and Benovic JL (2000) Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J Biol Chem 275, 26515-26522 https://doi.org/10.1074/jbc.M003542200
  60. Chen L and Feany MB (2005) Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 8, 657-663 https://doi.org/10.1038/nn1443
  61. Chen L, Periquet M, Wang X et al (2009) Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J Clin Invest 119, 3257-3265 https://doi.org/10.1172/JCI39088
  62. Sato H, Arawaka S, Hara S et al (2011) Authentically phosphorylated alpha-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease. J Neurosci 31, 16884-16894 https://doi.org/10.1523/JNEUROSCI.3967-11.2011
  63. Okochi M, Walter J, Koyama A et al (2000) Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J Biol Chem 275, 390-397 https://doi.org/10.1074/jbc.275.1.390
  64. Paleologou KE, Oueslati A, Shakked G et al (2010) Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. J Neurosci 30, 3184-3198 https://doi.org/10.1523/JNEUROSCI.5922-09.2010
  65. Prasad V, Wasser Y, Hans F et al (2019) Monitoring alpha-synuclein multimerization in vivo. FASEB J 33, 2116-2131 https://doi.org/10.1096/fj.201800148RRR
  66. Smith WW, Margolis RL, Li X et al (2005) Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J Neurosci 25, 5544-5552 https://doi.org/10.1523/JNEUROSCI.0482-05.2005
  67. Waxman EA and Giasson BI (2008) Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein. J Neuropathol Exp Neurol 67, 402-416 https://doi.org/10.1097/NEN.0b013e31816fc995
  68. Mbefo MK, Paleologou KE, Boucharaba A et al (2010) Phosphorylation of synucleins by members of the Pololike kinase family. J Biol Chem 285, 2807-2822 https://doi.org/10.1074/jbc.M109.081950
  69. Ding J, Wang Y, Huang J et al (2020) Role of alpha-synuclein phosphorylation at Serine 129 in methamphetamine-induced neurotoxicity in vitro and in vivo. Neuroreport 31, 787-797
  70. Oueslati A, Schneider BL, Aebischer P and Lashuel HA (2013) Polo-like kinase 2 regulates selective autophagic alpha-synuclein clearance and suppresses its toxicity in vivo. Proc Natl Acad Sci U S A 110, E3945-E3954
  71. Shin WH and Chung KC (2020) Death-associated protein kinase 1 phosphorylates alpha-synuclein at Ser129 and exacerbates rotenone-induced toxic aggregation of alpha-synuclein in dopaminergic SH-SY5Y cells. Exp Neurobiol 29, 207-218 https://doi.org/10.5607/en20014
  72. Nakamura T, Yamashita H, Takahashi T and Nakamura S (2001) Activated Fyn phosphorylates alpha-synuclein at tyrosine residue 125. Biochem Biophys Res Commun 280, 1085-1092 https://doi.org/10.1006/bbrc.2000.4253
  73. Ellis CE, Schwartzberg PL, Grider TL, Fink DW and Nussbaum RL (2001) alpha-synuclein is phosphorylated by members of the Src family of protein-tyrosine kinases. J Biol Chem 276, 3879-3884 https://doi.org/10.1074/jbc.m010316200
  74. Negro A, Brunati AM, Donella-Deana A, Massimino ML and Pinna LA (2002) Multiple phosphorylation of alpha-synuclein by protein tyrosine kinase Syk prevents eosininduced aggregation. FASEB J 16, 210-212
  75. Sorrentino ZA, Hass E, Vijayaraghavan N et al (2020) Carboxy-terminal truncation and phosphorylation of alpha-synuclein elongates survival in a prion-like seeding mouse model of synucleinopathy. Neurosci Lett 732, 135017 https://doi.org/10.1016/j.neulet.2020.135017
  76. Oueslati A, Paleologou KE, Schneider BL, Aebischer P and Lashuel HA (2012) Mimicking phosphorylation at serine 87 inhibits the aggregation of human alpha-synuclein and protects against its toxicity in a rat model of Parkinson's disease. J Neurosci 32, 1536-1544 https://doi.org/10.1523/JNEUROSCI.3784-11.2012
  77. Stefanis L, Emmanouilidou E, Pantazopoulou M, Kirik D, Vekrellis K and Tofaris GK (2019) How is alpha-synuclein cleared from the cell? J Neurochem 150, 577-590 https://doi.org/10.1111/jnc.14704
  78. Shin Y, Klucken J, Patterson C, Hyman BT and McLean PJ (2005) The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways. J Biol Chem 280, 23727-23734 https://doi.org/10.1074/jbc.M503326200
  79. Tetzlaff JE, Putcha P, Outeiro TF et al (2008) CHIP targets toxic alpha-Synuclein oligomers for degradation. J Biol Chem 283, 17962-17968 https://doi.org/10.1074/jbc.M802283200
  80. Davies SE, Hallett PJ, Moens T et al (2014) Enhanced ubiquitin-dependent degradation by Nedd4 protects against alpha-synuclein accumulation and toxicity in animal models of Parkinson's disease. Neurobiol Dis 64, 79-87 https://doi.org/10.1016/j.nbd.2013.12.011
  81. Tofaris GK, Kim HT, Hourez R, Jung JW, Kim KP and Goldberg AL (2011) Ubiquitin ligase Nedd4 promotes alpha-synuclein degradation by the endosomal-lysosomal pathway. Proc Natl Acad Sci U S A 108, 17004-17009 https://doi.org/10.1073/pnas.1109356108
  82. Meier F, Abeywardana T, Dhall A et al (2012) Semisynthetic, site-specific ubiquitin modification of alpha-synuclein reveals differential effects on aggregation. J Am Chem Soc 134, 5468-5471 https://doi.org/10.1021/ja300094r
  83. Hejjaoui M, Haj-Yahya M, Kumar KS, Brik A and Lashuel HA (2011) Towards elucidation of the role of ubiquitination in the pathogenesis of Parkinson's disease with semisynthetic ubiquitinated alpha-synuclein. Angew Chem Int Ed Engl 50, 405-409 https://doi.org/10.1002/anie.201005546
  84. Gerez JA, Prymaczok NC, Rockenstein E et al (2019) A cullin-RING ubiquitin ligase targets exogenous alpha-synuclein and inhibits Lewy body-like pathology. Sci Transl Med 11, eaau6722 https://doi.org/10.1126/scitranslmed.aau6722
  85. Ye Y, Klenerman D and Finley D (2020) N-terminal ubiquitination of amyloidogenic proteins triggers removal of their oligomers by the proteasome holoenzyme. J Mol Biol 432, 585-596 https://doi.org/10.1016/j.jmb.2019.08.021
  86. Moon SP, Balana AT, Galesic A, Rakshit A and Pratt MR (2020) Ubiquitination can change the structure of the alpha-synuclein amyloid fiber in a site selective fashion. J Org Chem 85, 1548-1555 https://doi.org/10.1021/acs.joc.9b02641
  87. Haj-Yahya M, Fauvet B, Herman-Bachinsky Y et al (2013) Synthetic polyubiquitinated alpha-Synuclein reveals important insights into the roles of the ubiquitin chain in regulating its pathophysiology. Proc Natl Acad Sci U S A 110, 17726-17731 https://doi.org/10.1073/pnas.1315654110
  88. Pountney DL, Huang Y, Burns RJ et al (2003) SUMO-1 marks the nuclear inclusions in familial neuronal intra-nuclear inclusion disease. Exp Neurol 184, 436-446 https://doi.org/10.1016/j.expneurol.2003.07.004
  89. Rott R, Szargel R, Shani V et al (2017) SUMOylation and ubiquitination reciprocally regulate alpha-synuclein degradation and pathological aggregation. Proc Natl Acad Sci U S A 114, 13176-13181 https://doi.org/10.1073/pnas.1704351114
  90. Kim YM, Jang WH, Quezado MM et al (2011) Proteasome inhibition induces alpha-synuclein SUMOylation and aggregate formation. J Neurol Sci 307, 157-161 https://doi.org/10.1016/j.jns.2011.04.015
  91. Abeywardana T and Pratt MR (2015) Extent of inhibition of alpha-synuclein aggregation in vitro by SUMOylation is conjugation site- and SUMO isoform-selective. Biochemistry 54, 959-961 https://doi.org/10.1021/bi501512m
  92. Shahpasandzadeh H, Popova B, Kleinknecht A, Fraser PE, Outeiro TF and Braus GH (2014) Interplay between sumoylation and phosphorylation for protection against alpha-synuclein inclusions. J Biol Chem 289, 31224-31240 https://doi.org/10.1074/jbc.M114.559237
  93. Krumova P, Meulmeester E, Garrido M et al (2011) Sumoylation inhibits alpha-synuclein aggregation and toxicity. J Cell Biol 194, 49-60 https://doi.org/10.1083/jcb.201010117
  94. Baba M, Nakajo S, Tu PH et al (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 152, 879-884
  95. Muntane G, Ferrer I and Martinez-Vicente M (2012) alpha-synuclein phosphorylation and truncation are normal events in the adult human brain. Neuroscience 200, 106-119 https://doi.org/10.1016/j.neuroscience.2011.10.042
  96. Campbell BC, McLean CA, Culvenor JG et al (2001) The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. J Neurochem 76, 87-96 https://doi.org/10.1046/j.1471-4159.2001.00021.x
  97. Iyer A, Roeters SJ, Kogan V, Woutersen S, Claessens M and Subramaniam V (2017) C-terminal truncated alpha-synuclein fibrils contain strongly twisted beta-sheets. J Am Chem Soc 139, 15392-15400 https://doi.org/10.1021/jacs.7b07403
  98. Hoyer W, Cherny D, Subramaniam V and Jovin TM (2004) Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro. Biochemistry 43, 16233-16242 https://doi.org/10.1021/bi048453u
  99. Mishizen-Eberz AJ, Norris EH, Giasson BI et al (2005) Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein. Biochemistry 44, 7818-7829 https://doi.org/10.1021/bi047846q
  100. Mishizen-Eberz AJ, Guttmann RP, Giasson BI et al (2003) Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro. J Neurochem 86, 836-847 https://doi.org/10.1046/j.1471-4159.2003.01878.x
  101. Kasai T, Tokuda T, Yamaguchi N et al (2008) Cleavage of normal and pathological forms of alpha-synuclein by neurosin in vitro. Neurosci Lett 436, 52-56 https://doi.org/10.1016/j.neulet.2008.02.057
  102. Terada M, Suzuki G, Nonaka T, Kametani F, Tamaoka A and Hasegawa M (2018) The effect of truncation on prion-like properties of alpha-synuclein. J Biol Chem 293, 13910-13920 https://doi.org/10.1074/jbc.RA118.001862
  103. Munch G, Luth HJ, Wong A et al (2000) Crosslinking of alpha-synuclein by advanced glycation endproducts--an early pathophysiological step in Lewy body formation? J Chem Neuroanat 20, 253-257 https://doi.org/10.1016/S0891-0618(00)00096-X
  104. Brahmachari S, Ge P, Lee SH et al (2016) Activation of tyrosine kinase c-Abl contributes to alpha-synuclein-induced neurodegeneration. J Clin Invest 126, 2970-2988 https://doi.org/10.1172/JCI85456
  105. Rott R, Szargel R, Haskin J et al (2008) Monoubiquitylation of alpha-synuclein by seven in absentia homolog (SIAH) promotes its aggregation in dopaminergic cells. J Biol Chem 283, 3316-3328 https://doi.org/10.1074/jbc.M704809200
  106. Lee JT, Wheeler TC, Li L and Chin LS (2008) Ubiquitination of alpha-synuclein by Siah-1 promotes alpha-synuclein aggregation and apoptotic cell death. Hum Mol Genet 17, 906-917 https://doi.org/10.1093/hmg/ddm363
  107. Oh Y, Kim YM, Mouradian MM and Chung KC (2011) Human Polycomb protein 2 promotes alpha-synuclein aggregate formation through covalent SUMOylation. Brain Res 1381, 78-89 https://doi.org/10.1016/j.brainres.2011.01.039
  108. Vijayakumaran S, Nakamura Y, Henley JM and Pountney DL (2019) Ginkgolic acid promotes autophagy-dependent clearance of intracellular alpha-synuclein aggregates. Mol Cell Neurosci 101, 103416 https://doi.org/10.1016/j.mcn.2019.103416
  109. Periquet M, Fulga T, Myllykangas L, Schlossmacher MG and Feany MB (2007) Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci 27, 3338-3346 https://doi.org/10.1523/JNEUROSCI.0285-07.2007
  110. Li W, West N, Colla E et al (2005) Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci U S A 102, 2162-2167 https://doi.org/10.1073/pnas.0406976102
  111. Zhang Z, Kang SS, Liu X et al (2017) Asparagine endopeptidase cleaves alpha-synuclein and mediates pathologic activities in Parkinson's disease. Nat Struct Mol Biol 24, 632-642 https://doi.org/10.1038/nsmb.3433
  112. McGlinchey RP, Lacy SM, Huffer KE, Tayebi N, Sidransky E and Lee JC (2019) C-terminal alpha-synuclein truncations are linked to cysteine cathepsin activity in Parkinson's disease. J Biol Chem 294, 9973-9984 https://doi.org/10.1074/jbc.RA119.008930
  113. Dufty BM, Warner LR, Hou ST et al (2007) Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation. Am J Pathol 170, 1725-1738 https://doi.org/10.2353/ajpath.2007.061232
  114. Serpell LC, Berriman J, Jakes R, Goedert M and Crowther RA (2000) Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci U S A 97, 4897-4902 https://doi.org/10.1073/pnas.97.9.4897
  115. Tofaris GK, Garcia Reitbock P, Humby T et al (2006) Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders. J Neurosci 26, 3942-3950 https://doi.org/10.1523/JNEUROSCI.4965-05.2006
  116. Murray IV, Giasson BI, Quinn SM et al (2003) Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry 42, 8530-8540 https://doi.org/10.1021/bi027363r
  117. Ni X, McGlinchey RP, Jiang J and Lee JC (2019) Structural insights into alpha-synuclein fibril polymorphism: Effects of Parkinson's disease-related C-terminal truncations. J Mol Biol 431, 3913-3919 https://doi.org/10.1016/j.jmb.2019.07.001
  118. van der Wateren IM, Knowles TPJ, Buell AK, Dobson CM and Galvagnion C (2018) C-terminal truncation of alpha-synuclein promotes amyloid fibril amplification at physiological pH. Chem Sci 9, 5506-5516 https://doi.org/10.1039/C8SC01109E
  119. Anderson JP, Walker DE, Goldstein JM et al (2006) Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281, 29739-29752 https://doi.org/10.1074/jbc.M600933200
  120. Luk KC, Song C, O'Brien P et al (2009) Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A 106, 20051-20056 https://doi.org/10.1073/pnas.0908005106
  121. Waxman EA and Giasson BI (2011) Characterization of kinases involved in the phosphorylation of aggregated alpha-synuclein. J Neurosci Res 89, 231-247 https://doi.org/10.1002/jnr.22537
  122. Machiya Y, Hara S, Arawaka S et al (2010) Phosphorylated alpha-synuclein at Ser-129 is targeted to the proteasome pathway in a ubiquitin-independent manner. J Biol Chem 285, 40732-40744 https://doi.org/10.1074/jbc.M110.141952
  123. Moons R, Konijnenberg A, Mensch C et al (2020) Metal ions shape alpha-synuclein. Sci Rep 10, 16293 https://doi.org/10.1038/s41598-020-73207-9
  124. Burmann BM, Gerez JA, Matecko-Burmann I et al (2020) Regulation of alpha-synuclein by chaperones in mammalian cells. Nature 577, 127-132 https://doi.org/10.1038/s41586-019-1808-9